Join us for a webinar “DNA methylation in biofluids: from genome-wide studies to targeted
approaches“ on March 11, 2021 at 5PM CET/11AM EST.
Measuring the methylation status of cell-free DNA (cfDNA) in liquid biopsy holds great promise for the early, non-invasive detection of cancer. Recently, clinical studies – including the Circulating Cell-free Genome Atlas Study - have showcased the successful application of cfDNA sequencing to detect and classify in multiple cancer types. We propose to detail the different DNA methylation profiling methods that aid in the identification and validation of epigenetic-based biomarkers for cancer.
We will be answering the following questions:
Why study cell-free DNA?
What is DNA methylation?
How can DNA methylation profiling be used for biomarker discovery?
How can DNA methylation profiling be used for biomarker validation?
Dr Matteo Tosolini received his PhD in Stem Cell Epigenetics in December 2016 from the University of Paris-Saclay. He has been working at Diagenode since 2016 as a Senior Scientist with expertise in cfDNA from biofluids and DNA methylation.